Obesity is a world-wide health problem, whose incidence and prevalence are rising steadily; it may be combined with hypertension, diabetes, dyslipidemia, atherosclerosis, and/or 
INTRODUCTION
With increasing the rate of obesity among adults and children, authorities view it as a serious public health problem. Between 1980 and 2000, obesity incidence among adults has more than doubled; and obesity among adolescents has tripled. In the USA, obesity is the second-leading cause of preventable death after smoking (1) . In Egypt, It has been reported that the prevalence of obesity in adults is very high, particularly among women, and that the prevalence of diabetes and hypertension parallels that of obesity (2) . Understanding of neuroendocrinal mechanisms regulating appetite metabolism and adiposity is revised since the discovery of leptin (3) . Leptin is an adipocyte-derived hormone that acts on the hypothalamus to regulate appetite, energy expenditure, and sympathetic outflow. Leptin promotes weight loss by reducing appetite and by increasing energy expenditure through stimulation of sympathetic nerve activity (4) . The excitement that followed leptin discovery was soon modulated by the realization that obesity is associated with hyperleptinemia, defining a state of "leptin resistance"
(5) . Leptin plays its role by interaction with the specific leptin receptor. The leptin receptor exists in several isoforms. A soluble form of leptin receptor (sLR) represents the main leptin-binding activity in human blood. Circulating sLR is derived from ectodomain shedding of membrane-bound receptors and/or by alternative splicing of leptin receptor mRNA. It modulates steady-state leptin levels by modifying circulating free leptin to protect the hormone from degradation and clearance. Binding of leptin with soluble leptin receptor has been suggested to increase the bioavailability of leptin in plasma as well as to decrease binding of leptin to membrane specific receptors (6) . When sLR is incubated with free leptin, the leptin-sLR complex is incapable of activating membrane-bound receptors, although it does not inhibit the action of free leptin (7) . The risk of hypertension is fivetimes higher in the obese subjects as compared to those of normal weigh (8) . The mechanisms linking obesity to the development of hypertension have not been well-identified (9) . Atrial natriuretic peptide (ANP) is a circulating neurotransmitter regulating salt and water homeostasis and vascular tone that control blood pressure. It is cardiac in origin and is secreted mainly in response to increased intra-atrial pressure (10) . Abdel Hafez et al. (11) reported rise in plasma ANP in obesity, which became more elevated if the obesity was associated with hypertension.
The present work was planned to study the interaction of leptin and atrial natriuretic peptide in pathogenesis of hypertension in middle-aged obese females.
SUBJECTS & METHODS
Seventy-five female subjects were enrolled in this study. They were divided according to body mass index (BMI) and blood pressure (BP) into the following groups: Group 1: Healthy lean controls (n =15), with age ranged between 22-47 years, BMI ≤25 kg/ m 2 and BP ≤120/80 mmHg. Group II: Obese normotensive patients (n =30), with age ranged between 20-47 years, BMI ≥30 kg/m 2 and BP ≤120/80 mmHg.
Group III:
Obese hypertensive patients (n =30), with age ranged between 21-48 years, BMI ≥30 kg/m 2 and BP ≥ 140/90 mmHg. They presented with never-treated, uncomplicated essential (primary) hypertension.
All patients were recruited from the Outpatients' Clinic of Internal Medicine Section, Kasr Al-Aini Hospital, Cairo University. The control volunteers were females from the working staff. All participants gave their informed consent before participation in the study, and the Ethics Committee of Kasr Al-Aini Hospital approved the protocol of the study.
For all subjects, arterial blood pressure was measured in the right arm by mercury sphygmomanometer three times while subjects were in a complete physical and mental rest (i.e. sitting or supine for at least 5.0 minutes before measurement) in a quite room at ambient temperature. Average values were calculated for diastolic and systolic pressures, large cuff sizes were used in obese subjects. BP values ≤120/80 mmHg were considered normotensive, while values ≥ 140/90 mmHg were considered hypertensive (12) . Detailed history taking, physical examination and laboratory investigations were done to exclude acute illness, cardiac, hepatic, renal, gastrointestinal, endocrinal, or malignant disease that might affect the parameters under investigation. None of the patients was receiving drugs known to affect the investigated parameters.
To minimize the effect of sex and age on the results of this work, all subjects were females aged 20-47 years old and not receiving contraceptive or hormonal therapy. Blood sampling was performed early in the follicular phase of the menstrual period (within the first week of the cycle).
Analytic procedures:
Following an overnight fast (12 hours), 10 ml blood was collected from the antecubital vein, and serum was kept frozen, in aliquots, at -20°C until used. The following laboratory investigations were performed for each subject: fasting blood glucose 
RESULTS
The clinical characteristics and anthropometric measurements (mean ± SD) in healthy control (Group I), obese normotensive (Group II) and obese hypertensive subjects (Group III) are shown in table (I). The serum levels of creatinine, leptin and ANP were significantly higher in groups II and III versus group I. Also, these levels were significantly higher in group III when compared to group II (Table II) .
The serum sLR level in groups II and III was significantly lower than group I. Serum sLR level in group III was significantly lower than its level in group II (Table II) . 
DISCUSSION
Leptin, as adipocytokiune is derived from adipose tissue, it is significantly elevated in obese groups versus lean control group, with significant positive correlation between serum leptin concentration and BMI in all studied groups.
Mackintosh and Hirsch (21) reported that females with increased fat mass are associated with higher baseline leptin levels and endogenous production rates. Several other studies demonstrated that increased adiposity is correlated with increased serum leptin levels secondary to increased production rate and decreased elimination (22,23) . In addition, Hafeezullah (24) confirmed increased production rate through reporting higher concentration of leptin mRNA in fat from obese compared to thin subjects. The latter finding suggests that leptin gene is expressed more in adipose tissue of obese than from lean subjects. The underlined mechanism affecting the rate of gene expression is not clear.
In the present study the serum levels of leptin were significantly higher in group III than in groups II and I. Also, a significant positive correlation was detected between serum leptin and both systolic and diastolic blood pressures in all studied groups. This suggests that blood pressure might be affected by circulating leptin, or a common effector on leptin level and blood pressure is playing a role. Al-Hazimi and Syiamic (25) suggested that serum leptin and angiotensin II levels were strong predictors of elevated blood pressure in obese women.
El-Gharbawy and co-workers (26) found that leptin levels were higher in hypertensive than in normotensive African Americans, but once these individuals were adjusted for obesity, no significant relationship was further observed between leptin and blood pressure. 42,43) . The relationship of sLR with the degree of adiposity suggests that high sLR levels may enhance leptin action in lean subjects more than in obese subjects (44) , and in lean subjects leptin circulates mainly in the bound form, whereas in obese subjects the majority of leptin circulates in the free form (6) . In the present study, there was a significant negative correlation between serum sLR and both BMI and leptin in the whole studied population. Circulating sLR expresses how leptin receptors are bioactive. In obesity, characterized by hyperleptinemia and leptin resistance, there may be downregulation of leptin receptors, resulting in reduced circulating sLR (45) . Huang et al.
and Gajewska et al.
(6) had reported that the sLR showed a significant inverse correlation with leptin and percentage of body fat.
Because the natriuretic peptide system plays a key role in the regulation of renal handling of sodium and water, it has been speculated that obese individuals may have an impaired natriuretic peptide response. In a study in our laboratory, raised serum ANP was observed in obese subjects with and without hypertension (11) . In the present study, ANP levels of obese hypertensive and obese normotensive subjects had significantly higher serum ANP level than that of the lean control subjects. Also, the mean serum ANP level of obese hypertensive subjects was significantly higher than ANP level of obese normotensive. There was a significant positive correlation between serum ANP level and systolic BP, diastolic BP and BMI in the whole studied population.
Numerous studies reported high concentrations of ANP in patients with arterial hypertension regardless of body weight (46,47,48) . Rise of serum ANP in obesity may be a pathophysiologic mechanism to protect against the hemodynamic changes that are associated with expanded blood volume in obesity and hypertension (11) . ANP is known to be vasodilator and an inhibitor to rennin-angiotensinaldosterone axis, besides its diuretic and natriuretic effects (49) . In the study of Wang and coworkers (50) , plasma natriuretic peptide levels were, variably, higher in hypertensive compared with normotensive individuals. However, in contradiction to our results they reported that overweight and obese individuals with hypertension still had lower plasma ANP level compared with normotensive individuals with normal BMI. Natriuretic peptides, in obese patients with hypertension may protect against further elevation of blood pressure rather than contribute to the pathogenesis of hypertension by guarding against fluid volume expansion.
In this study, a significant positive correlation was detected between serum ANP level and leptin, while a significant negative correlation was found between serum ANP level and sLR in the whole studied groups. Such correlation suggests that ANP may influence leptin receptor activity. Both leptin and ANP enhance sympathetic overactivity (51) . Atrial natriuretic peptide has been shown to promote adipose tissue lipolysis through cGMP-mediated hormone-sensitive lipase activation (52,53) .
Nielsen et al. (54)
suggested that the increased release of free fatty acids (FFA) into the portal vein from lipolysis in visceral fat depots of obese subjects could explain the strong association between visceral obesity and increased sympathetic nerve outflow and blood pressure. Obesity-associated hyperinsulinemia may be a crucial pathophysiologic feature of promoted lipolysis in visceral adipose tissue Fatty acid binding protein-2 may undergo mutation in metabolic syndrome, this impaired fatty acid utilization may ensue resulting in enhanced sympathetic activity (56) . In addition, Mascareno et al.
(57) , investigated the molecular mechanism(s) that play a role in leptin signaling during the development of left ventricular hypertrophy due to pressure overload (i.e. hypertension), and they observed that leptin plays a role in modulating the transcriptional activity of nuclear factor activated T cell 4 which is the promoter of the ANP gene, followed by an increase in the expression of the ANP gene. Increased ANP in patients with idiopathic hypertension might indicate left ventricular hypertrophy, in which the increased left ventricular mass may significantly enhance the ventricular contribution of circulating ANP (58) . Thus, it seems that an interaction between leptin and ANP in development of hypertension in obese subjects may exist. The interaction may aim at reduction of the circulating plasma volume besides adapting for energy homeostasis.
Serum glucose in obese groups is significantly higher than the lean control group. Insulin has a sustained antinatriuretic action that is triggered by increased glucose, and it is powerful enough to completely block the natriuresis caused by hyperglycemia (38) . This action of insulin may be an etiological factor of sodium retention in obesity with subsequent rise of blood pressure.
To 
